X0202 SCHEDULE 13G/A 0001104659-25-078696 0001502725 XXXXXXXX LIVE 1 Common Stock, $0.01 par value 03/31/2026 0001372514 KIORA PHARMACEUTICALS, INC. 49721T507 169 Saxony Rd. Suite 212 Encinitas CA 92024 Rule 13d-1(c) NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP MA 0.00 148736.00 0.00 148736.00 148736.00 N 3.388 PN KIORA PHARMACEUTICALS, INC. 169 Saxony Rd., Suite 212, Encinitas, CA, 92024 NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP ("Nantahala") 130 Main St. 2nd Floor, New Canaan, CT 06840 Nantahala is a Massachusetts limited partnership. Y As of March 31, 2026, Nantahala may be deemed to be the beneficial owner of 148,736 Shares. The 148,736 Shares includes 148,736 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants. As of March 31, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of 3.388% of the total number of Shares outstanding, based on 4,431,940 shares outstanding per the 10Q filed on May 8, 2026. 0 148,736 0 148,736 N Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP /s/ Taki Vasilakis 05/15/2026 /s/ Wilmot B. Harkey 05/15/2026 /s/ Daniel Mack 05/15/2026